Skip to main content
Premium Trial:

Request an Annual Quote

Sloan-Kettering Joins Sigma-Aldrich's RNAi Partnership Program

NEW YORK (GenomeWeb News) – Memorial Sloan-Kettering Cancer Center has joined Sigma-Aldrich’s RNAi Partnership Program, the St. Louis, Mo.-based firm said today.
 
Sigma-Aldrich said that members of the program gain access to products in its functional genomics portfolio including shRNA libraries developed by the RNAi Consortium that target more than 15,000 human genes and 15,000 mouse genes. Sigma-Aldrich is a member of the RNAi Consortium.
 
The RNAi Consortium was established by the Broad Institute in 2004. The public/private alliance of RNAi researchers is developing genome-scale sets of virally expressed shRNAs targeting mouse and human genes.
 
New York City-based Sloan-Kettering joins a list of academic and other research institutes including the Cleveland Clinic, the Harvard Stem Cell Institute, Washington University of St. Louis, Princeton University, the Wistar Institute, and Rutgers University, as members of the program.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.